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The transcription factor ets-2 was phosphorylated at residue threonine 72 in a colony-stimulating factor 1
(CSF-1)- and mitogen-activated protein kinase-independent manner in macrophages isolated from motheaten-
viable (me-v) mice. The CSF-1 and ets-2 target genes coding for Bcl-x, urokinase plasminogen activator, and
scavenger receptor were also expressed at high levels independent of CSF-1 addition to me-v cells. Akt (protein
kinase B) was constitutively active in me-v macrophages, and an Akt immunoprecipitate catalyzed phosphor-
ylation of ets-2 at threonine 72. The p54 isoform of c-jun N-terminal kinase–stress-activated kinase (JNK-
SAPK) coimmunoprecipitated with Akt from me-v macrophages, and treatment of me-v cells with the specific
phosphatidylinositol 3-kinase inhibitor LY294002 decreased cell survival, Akt and JNK kinase activities, ets-2
phosphorylation, and Bcl-x mRNA expression. Therefore, ets-2 is a target for phosphatidylinositol 3-kinase–
Akt–JNK action, and the JNK p54 isoform is an ets-2 kinase in macrophages. Constitutive ets-2 activity may
contribute to the pathology of me-v mice by increasing expression of genes like the Bcl-x gene that promote
macrophage survival.
Macrophage colony-stimulating factor 1 (CSF-1) and its cog-
nate receptor tyrosine kinase c-fms control the proliferation,
differentiation, and survival of cells of the mononuclear phago-
cyte cell lineage by activating multiple signaling pathways (re-
viewed in reference 35). One effect of these signaling events in
macrophages is the stable, persistent expression of specific
genes. For example the urokinase plasminogen activator
(uPA) gene (41), the scavenger receptor A (SR) gene (48), and
the Bcl-x gene (38) are all targets of CSF-1 action. The ETS
family member ets-2 regulates these three CSF-1 target genes
(38, 48, 49).
ets-2 is activated by ras-dependent phosphorylation of thre-
onine residue 72, and CSF-1–c-fms signaling leads to persistent
phosphorylation of this site (16, 49). Activation of the ras–raf–
MEK-1–Erk protein kinase cascade by CSF-1 leads to rapid
and persistent phosphorylation of ets-2 in fibroblasts engi-
neered to express exogenous c-fms as well as in macrophage
cell lines or primary bone marrow-derived macrophages
(BMMs). The MEK inhibitor PD98059 abrogates ets-2 phos-
phorylation in response to CSF-1–c-fms signaling in the fibro-
blast model system (16).
One unanswered question is the precise role of ets-2 in
CSF-1–c-fms signaling. Does activation of ets-2 by CSF-1 con-
tribute to mitogenic growth, differentiation, or cell survival?
Expression of a dominant-negative ets-2 protein in macro-
phages in transgenic mice resulted in accelerated apoptosis
following CSF-1 deprivation (24). In the macrophage cell line
BAC1.2F5, overexpression of ets-2 promoted survival of cells
in the absence of CSF-1 (38). These observations indicate that
ets-2 may be involved in CSF-1-dependent survival of macro-
phages.
The mouse motheaten (me) and motheaten-viable (me-v) mu-
tants are the result of point mutations that affect splicing of
transcripts encoded by the src-homology 2 tyrosine phospha-
tase 1 gene (SHP-1, also termed hematopoietic cell phospha-
tase) and lead to expression of proteins with greatly diminished
tyrosine phosphatase activity (39, 44). These mutant mice ac-
cumulate massive numbers of macrophages and neutrophils in
the peripheral tissues, including skin, spleen and lung, and
subsequently succumb to an interstitial pneumonia (reviewed
in reference 7). The me-v mutant mice also develop an inflam-
matory disease resembling rheumatoid arthritis (30). SHP-1
apparently plays a central role in cell signaling events that
regulate macrophage-dependent inflammatory responses.
SHP-1 may be a negative regulator of CSF-1 signaling (10).
SHP-1 is phosphorylated on tyrosine following CSF-1 stimula-
tion of macrophages, but does not directly bind to ligand-
activated c-fms (50). CSF-1 treatment of primary macrophages
obtained from me mice is reported to result in c-fms hyper-
phosphorylation, increased phosphorylation of signaling mol-
ecules known to be downstream of c-fms, and an increased rate
of macrophage proliferation (10). However, another group
reported that CSF-1 mitogenic signaling is unaffected in mac-
rophages obtained from me or me-v mice, but that granulocyte-
macrophage (GM)-CSF mitogenic signaling is hyperactivated
in such macrophages (23). SHP-1 forms a complex with Janus
kinase family members, including JAK2 (22), and also forms a
complex with two members of a family of receptors involved in
negative regulation in the immune system, PIR-B (p91A) and
SHPS-1 (BIT) (6, 42, 46). Integrin-mediated adhesion is re-
ported to be altered in me-v macrophages, and this change in
cell adhesion correlates with a two- to fivefold increase in
phosphatidylinositol 3-kinase (PI 3-kinase) activity in me-v
cells compared to wild-type cells (33).
* Corresponding author. Mailing address: Department of Molecular
Genetics, Ohio State University, 484 W. 12th Ave., Columbus, OH
43210. Phone: (614) 688-3824. Fax: (614) 688-8727. E-mail: ostrowski
.4@osu.edu.
8026
Interestingly, it has been reported that CSF-1 does not ac-
tivate MEK-1 and Erks in primary macrophages obtained from
mice homozygous for the me-v mutation, implying a positive
role for SHP-1 in CSF-1 activation of MEK-1 and Erks (31).
This observation suggests that studying the me-v mouse model
might reveal MEK/Erk-independent pathways leading to ets-2
phosphorylation and activation in macrophages. To test this
hypothesis, the phosphorylation of ets-2 in primary macro-
phages derived from me-v mice was analyzed.
The studies reported here provide evidence for constitutive
phosphorylation of ets-2 by the PI 3-kinase/Akt pathway in
me-v macrophages. These studies indicate that the p54 isoform
of JNK (SAPK) can be found in a complex with Akt in mac-
rophages and that p54 JNK likely is an ets-2 kinase active in
me-v macrophages. Phosphorylation of ets-2 correlated with
expression of previously identified CSF-1 target genes, includ-
ing the antiapoptotic Bcl-x gene (38). In transient transfection
assays, the promoter for the mouse Bcl-x gene was superacti-
vated over 90-fold by the combination of ets-2 and a mem-
brane-targeted form of Akt. Phosphorylation of ets-2 and ac-
tivation of target gene expression were found to correlate with
increased me-v macrophage survival. In me-v macrophages,
both ets-2 phosphorylation and CSF-1-independent cell sur-
vival depend largely on a constitutive PI 3-kinase/Akt pathway.
These results indicate that constitutive ets-2 activity may con-
tribute to the pathology of me-v mice by regulating expression
of genes that promote cell survival in macrophages.
MATERIALS AND METHODS
Cell culture, Northern analysis, and transfections. The methods for culturing
RAW264 cells and for DNA-mediated transfection have been described previ-
ously (16). RNA was isolated and analyzed by Northern blotting as previously
described (16). The method for deriving BMMs has been described previously
(41). Briefly, bone marrow cells were cultured in RPMI containing 5% heat-
denatured fetal calf serum and supplemented with 50 ng of CSF-1 per ml for 5
days. At this point, BMMs were deprived of CSF-1 for 8 to 24 h and then
restimulated with CSF-1 (50 ng/ml) for various times as indicated. For experi-
ments with the PI 3-kinase inhibitor LY294002 (AG Scientific, Inc., San Diego,
Calif.) cells were treated with 100 mM drug for 15 min prior to stimulation.
The me-v mice were obtained from Jackson Laboratories. The mutation is in
the background C57BL/6J, and mice of this strain were used as controls (wild
type). All mice were genotyped by a method involving PCR amplification of the
region containing the me-v point mutation (39) directly from genomic DNA. The
amplified DNA was hybridized to labeled 15-mers representing the wild-type
sequence and the me-v lesion. DNA from wild-type or homozygous mutant mice
hybridized to either one of these probes, respectively, while DNA from mice
heterozygous for the mutation hybridized to both.
Immunohistochemistry. BMMs were cultured in Lab-Tek two-well chamber
slides (NUNC). Cells were deprived of CSF-1 for 24 h and stimulated for 8 h with
50 ng of CSF-1 per ml. Cells were washed in Tris-buffered saline (TBS) (50 mM
Tris [pH 7.5], 150 mM NaCl), fixed for 30 min in 4% paraformaldehyde, washed
three times with TBS, and permeabilized for 5 min with TBS containing 1%
Triton X-100. Endogenous peroxide activity was blocked by incubation with 0.1%
hydrogen peroxide and 10% methanol in TBS. Cells were washed and treated
with 2% normal goat serum in TBS. The affinity-purified phosphothreonine
72-specific anti-ets-2 antibody (16) was used at a 1:75 dilution for 2 h at room
temperature and followed by three washes with TBS containing 0.2% NP-40.
Antirabbit immunoglobulin G conjugated with biotin (Boehringer Mannheim)
was incubated for 1 h at a 1:200 dilution and washed as described above. A
1:2,000 dilution of streptavidin-horseradish peroxidase (Boehringer Mannheim)
was used for 1 h and washed in TBS. Antibody binding was detected with the
metal-enhanced 3,39-diaminobenzidine substrate kit (Pierce Biochemicals).
Immune kinase assays and Western analysis. Antibodies for phosphotyrosine
residues, Erks, Akt, and JNK were purchased commercially (Upstate Biotech-
nology or Santa Cruz Biotechnology). Akt assays were also confirmed with an
antibody kindly provided by Phil Tsichlis. The procedures for Erk immune kinase
assays have been described previously (16). The procedures for Akt kinase assays
have been described previously (21). The substrates employed for Erk, Akt, and
JNK assays were a recombinant ets-2 protein corresponding to amino acids 60 to
167 (16), histone H2B (Sigma), and a glutathione S-transferase–jun fusion pro-
tein representing amino acids 1 to 79 of c-jun (25). Phosphorylated products
produced in immune kinase assays were quantitated with a Molecular Dynamics
PhosphorImager. Western analysis was performed as previously described (16)
with a Lumi-Imager for quantification (Boehringer Mannheim).
Cell apoptosis and viability assays. Three assays were used to determine cell
apoptosis and cell viability. The first was a flow cytometry assay that measured
fragmented DNA indicative of apoptotic cells (reviewed in reference 11). Briefly,
cells were fixed in 70% ethanol, fragmented DNA was extracted with phosphate-
buffered saline containing 1 mg of RNase per ml, 10 mM sodium citrate, and
0.1% Triton X-100 (30 min at 37°C), and total DNA was stained with propidium
iodide (50 mg/ml) for 15 min. Samples were analyzed by flow cytometry (Becton-
Dickinson FACSCalibur). The peak of DNA appearing just before the G1-
specific peak (the sub-G0 peak, or hypodiploid peak) was quantitated by using
ModFit LT; version 2.0 software (Verity Software House, Topsham, Maine). The
ratio of this sub-G0 DNA peak to the total DNA recovered is equivalent to the
fraction of apoptotic cells. The second assay depended on the striking change in
nuclear morphology that occurs in macrophages undergoing apoptosis. Cells
were fixed with 3.7% paraformaldehyde in phosphate-buffered saline and stained
with 10 mM bis-benzamide (Sigma) for 5 min at room temperature. Nuclear
morphology was examined by fluorescent microscopy with an Eclipse E800 mi-
croscope (Nikon). Images were captured with MicroMax camera (Princeton
Instruments, Inc.). Two hundred to 300 cells were counted and scored as viable
or apoptotic based on nuclear morphology, and each experiment was performed
in duplicate. The third assay employed was a trypan blue dye exclusion assay to
measure cell viability. The results from all three assays were identical.
RESULTS
Phosphorylation of ets-2 and expression of ets-2 target
genes in me-v macrophages are independent of exogenous
CSF-1 and Erk activity. CSF-1 stimulates phosphorylation of
ets-2 at threonine residue 72 via the raf/MEK/Erk pathway
(16). However, the mitogen-activated protein (MAP) kinases
Erk-1 and Erk-2 are reported not to be responsive to CSF-1
stimulation of macrophages isolated from me-v mice (31). To
examine whether Erk-independent phosphorylation of ets-2
can occur in macrophages, the phosphorylation of ets-2 at
threonine residue 72 was monitored in primary macrophages
isolated from mice homozygous for the me-v mutation. For
these experiments, a polyclonal antibody that specifically rec-
ognizes the phosphothreonine 72-modified version of ets-2 was
employed (16). Immunohistochemistry with this antibody dem-
onstrated that low levels of phosphorylated ets-2 were detected
in wild-type BMMs deprived of CSF-1, but that nuclear phos-
pho-ets-2 could be readily detected in these cells treated with
CSF-1 (Fig. 1A). If nonimmune serum was substituted in the
analysis, no histochemical signal was detected (Fig. 1A). Ex-
periments using BMMs derived from me-v mice produced an
unexpected result. In these cells, ets-2 was expressed and phos-
phorylated in a manner independent of addition of exogenous
CSF-1 (Fig. 1A).
In order to confirm these results, extracts prepared from
both wild-type and me-v macrophages that had been deprived
of CSF-1 for 12 h or grown continuously in the presence of
CSF-1 were analyzed by Western blotting with the discriminat-
ing anti-phospho-ets-2 antibody or a nondiscriminating ets-2
antibody (Fig. 1B, top and bottom panels, respectively). For
wild-type cells, the removal of CSF-1 for 12 h resulted in a
slight 1.8-fold decrease in ets-2 steady-state levels and a more
significant 8-fold decrease in levels of phosphothreonine 72
ets-2 (Fig. 1B, compare lanes 1 and lane 3). In contrast, phos-
phorylated ets-2 levels in me-v BMMs were insensitive to with-
drawal of CSF-1 for 12 h (Fig. 1B, lanes 2 and 4). In addition,
ets-2 was phosphorylated in primary macrophages derived
from spleens of me-v mice that had been cultured in the ab-
sence of CSF-1 for 48 h (Fig. 1B, lanes 5 and 6). Even after 72 h
of CSF-1 withdrawal, the amount of phosphorylated ets-2 de-
tected in me-v BMMs did not change (data not shown). The
level of phosphorylated ets-2 in me-v macrophages deprived of
CSF-1 was equivalent to the levels observed in CSF-1-treated
wild-type cells (Fig. 1B, compare lanes 2 and 3).
Immune kinase assays using Erk-specific antibodies corrob-
orated that Erks were not transiently activated following 12
min of CSF-1 treatment of BMMs derived from me-v mice
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(Fig. 1C, left panel, wild-type BMMs; right panel, me-v BMMs)
(31). Additionally, persistent activation of Erks after 24 h of
CSF-1 stimulation (16) was not observed in me-v cells (Fig.
1C).
Two well-defined target genes of the CSF-1/ets-2 pathway in
macrophages are those coding for uPA (16, 41) and SR (48).
As demonstrated in Fig. 2, the levels of expression of uPA and
SR mRNAs were approximately eightfold higher in wild-type
BMMs grown in the presence of CSF-1 than those in cells
deprived of CSF-1 (Fig. 2A and B, lane 2 versus lane 1). In
me-v BMMs, uPA and SR mRNAs were expressed at high
levels whether or not CSF-1 was present (Fig. 2A and B, lanes
3 and 4). Levels of expression of uPA and SR mRNAs were
also found to be CSF-1 independent in primary spleen macro-
phages cultured from me-v mice (Fig. 2A and B, lanes 5 and 6).
The phosphorylation of ets-2 in me-v macrophages correlated
with increased expression of target genes.
An Akt immunoprecipitate catalyzes ets-2 phosphorylation
in vitro, and the PI 3-kinase inhibitor LY294002 diminishes
levels of phosphorylated ets-2 in vivo. The results presented
above indicated that Erk-independent phosphorylation and ac-
tivation of ets-2 occurred in me-v macrophages. One potential
candidate for the Erk-independent pathway is the PI 3-kinase/
Akt pathway. The PI 3-kinase/Akt pathway can be activated in
a ras-dependent or ras-independent fashion (17, 34) and has
been implicated in growth, differentiation, and survival path-
ways in many cell types, including myeloid cells (8, 32). Addi-
tionally, a recent report demonstrated that membrane-associ-
ated PI 3-kinase levels were two- to fivefold higher in me-v
macrophages than in wild-type cells (33), a result that we have
reproduced in our laboratory (data not shown).
As a first step, Akt immunoprecipitates prepared from the
macrophage cell line RAW264 were assayed for ets-2 kinase
activity (Fig. 3A). For these experiments, either the character-
ized Akt substrate histone H2B or a recombinant ets-2 poly-
peptide corresponding to the “pointed” domain (amino acids
67 to 170) (16) was used as a substrate. In immune kinase
assays, Akt immunoprecipitates were able to phosphorylate
either histone H2B or the ets-2 substrate following treatment
of cells with the cell-permeable tyrosine phosphatase inhibitor
pervanadate (3) (Fig. 3A, lane 2 versus lane 1). Phosphoryla-
tion of both histone H2B and ets-2 substrates was inhibited by
inclusion of the specific PI 3-kinase inhibitor LY294002 in
addition to pervanadate (47) (Fig. 3A, lanes 3 and 4, 50 and
100 mM, respectively).
To test whether an Akt immunoprecipitate catalyzed phos-
phorylation of the ets-2 substrate at residue threonine 72, the
wild-type substrate was compared to a substrate that had ala-
nine substituted for threonine at position 72 (16). While the
threonine 72 ets-2 protein was a substrate in the Akt immune
kinase assay, the alanine 72 substrate was not (Fig. 3A, [ets-2
A72 panel]), indicating that the Akt-associated ets kinase ac-
tivity phosphorylated the same residue of ets-2 as the raf/Erk
pathway (16).
To assess whether the Akt pathway could be responsible for
the constitutive phosphorylation of ets-2 observed in macro-
phages isolated from me-v mice, Akt kinase activities were
measured in wild-type and me-v macrophages (Fig. 3B). Both
histone H2B and ets-2 substrates were used for this analysis,
and identical results were obtained for both substrates (Fig.
3B, top panel versus bottom panel). Akt activity increased
about threefold following restimulation of wild-type macro-
phages deprived of CSF-1 in the representative experiment
presented (Fig. 3B, lane 2 versus lane 1) and then returned to
basal levels following 30 min of CSF-1 treatment (Fig. 3B, lane
3). Pretreatment of cells with LY294002 resulted in a threefold
inhibition of CSF-1-dependent Akt activity (Fig. 3B, lane 4). In
FIG. 1. ets-2 is persistently phosphorylated at residue threonine 72 in me-v
macrophages. (A) Detection of phosphorylated ets-2 by immunohistochemistry.
Cells were grown for 24 h without CSF-1, fixed, and incubated with ets-2 phos-
phothreonine antibody (2CSF-1) or stimulated for 8 h with 50 ng of CSF-1 per
ml prior to fixation and incubation with either the same ets-2 antibody (1CSF-1)
or nonimmune serum (NI). The dark nuclear staining indicates reactivity for
ets-2 phosphothreonine 72 antibody. WT, wild type. (B) ets-2 phosphorylation
detected in nuclear extracts by Western analysis with the same ets-2 antibody as
in panel A (top panel) or an antibody that detects ets-2 regardless of phosphor-
ylation status (bottom panel). Extracts were prepared from BMMs derived from
wild-type cells (lanes 1 and 3), from BMMs pooled from three me-v mice (lanes
2 and 4), or from spleen macrophages pooled from three me-v mice (lanes 5 and
6). Cells were grown without CSF-1 for 12 h (lanes 1 and 2) or 48 h (lanes 5) or
continuously with 50 ng of CSF-1 per ml (lanes 3, 4, and 6). (C) BMMs derived
from wild-type or me-v mice, as indicated, were grown without CSF-1 for 16 h
and then stimulated with 50 ng of CSF-1 per ml for the times indicated. Erk
immune kinase assays were performed by using the ets-2 “pointed” domain
recombinant protein substrate. The phosphorylated ets-2 substrate was detected
by autoradiography (top panel), while Western blots using an anti-Erk antibody
demonstrated that equal amounts of Erks were immunoprecipitated (bottom
panel).
FIG. 2. The ets-2 target genes coding for uPa and SR are expressed in a
CSF-1-independent fashion in me-v macrophages. Pooled macrophages (three
mice) were grown in medium lacking CSF-1 for 24 h (2CSF) or stimulated with
50 ng of CSF-1 per ml for 8 h following cytokine starvation (1CSF). Total RNA
was prepared and analyzed by Northern blotting. (A) Expression of uPA mRNA
in wild-type (WT) BMMs (lanes 1 and 2), me-v (MeV) BMMs (lane 3 and 4), or
me-v spleen macrophages (lanes 5 and 6). The arrow indicates the position of the
2.2-kb mRNA for uPA. (B) Expression of SR mRNA in wild-type BMMs (lanes
1 and 2), me-v BMMs (lane 3 and 4), or me-v spleen macrophages (lanes 5 and
6). The arrows indicate the position of the SR type I or type II mRNA (4 and 3.2
kb, respectively). Blots in both panels were reprobed with a mouse g-actin probe
as a control for sample loading (bottom panels).
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comparison, Akt activity in me-v cells was already 2.8-fold
greater than the wild-type cell basal activity in the absence of
exogenous CSF-1 (Fig. 3B, lanes 5). Akt activity was not sig-
nificantly increased by treatment of cells with CSF-1 for 5 or 30
min (Fig. 3B, lanes 6 and 7, respectively). Pretreatment of cells
with LY294002 resulted in a threefold inhibition of CSF-1-
independent Akt activity with either of the histone H2B or
ets-2 substrates (Fig. 3B, lane 8).
Four independent Akt immune kinase experiments with the
ets-2 substrate demonstrated that the results were reproduc-
ible, and the differences between wild-type and me-v cells were
significant (Fig. 3C). The analysis suggested that an Akt-asso-
ciated kinase can phosphorylate ets-2 in a CSF-1-dependent,
transient manner in wild-type cells. However, in me-v cells, the
Akt-associated ets-2 kinase activity was constitutive.
To establish a direct link between PI 3-kinase–Akt activation
and ets-2 activation, the phosphorylation of ets-2 following
LY294002 treatment of macrophages was examined by West-
ern analysis (Fig. 3D, top panel). This analysis revealed that
100 mM LY294002 caused an approximately 1.5-fold reduction
in phosphorylated ets-2 in wild-type cells grown in the presence
of CSF-1 (Fig. 3D, lane 1 versus lane 2). The inability of
LY294002 to inhibit ets-2 phosphorylation in wild-type cells
likely reflected that Erks are fully active and capable of phos-
phorylating ets-2 (16) (Fig. 1C). However, treatment of me-v
cells with 100 mM LY294002 for 16 h diminished the level of
phosphorylated ets-2 about sixfold compared to that in un-
treated cells (Fig. 3D, lane 4 versus lane 3). The PI 3-kinase
inhibitor wortmannin also decreased ets-2 phosphorylation in
me-v cells (data not shown). ets-2 phosphorylation was depen-
dent on the PI 3-kinase/Akt pathway in me-v BMMs.
JNK p54 isoform coimmunoprecipitates with Akt in me-v
macrophages and has ets-2 kinase activity. The threonine 72
ets-2 phosphorylation site is a proline-directed site (PLLTP)
that is closely related to the optimal Erk phosphorylation site
[PL(S/T)P] (2). However, this site is distinct from the consen-
sus Akt substrate site [RXRXX(S/T) (hydrophobic residue)]
(1). This implied that ets-2 was probably not directly phosphor-
ylated by Akt, but rather by a kinase that coimmunoprecipi-
tated with Akt. The sequence of the ets-2 site suggested that
another MAP kinase family member might be a candidate for
the Akt-associated kinase. JNKs were selected as the most
likely candidates, because there is evidence linking JNK kinase
activation to the PI 3-kinase pathway in several cell types (4,
28, 43).
To determine if JNKs were in a complex with Akt in me-v
macrophages, an anti-Akt antibody was used to immunopre-
cipitate Akt and associated proteins, and the complex was
analyzed by Western blotting with an anti-JNK antibody that
recognizes all three known JNK family members and their
isoforms (see Materials and Methods). The immunoprecipi-
tates were compared to a whole-cell extract prepared from
me-v BMMs (Fig. 4A). The analysis demonstrated that both
the p54 and p46 major isoforms of JNK were expressed in
BMMs and that the p46 isoform was about twofold more
abundant than the p54 isoform (Fig. 4A, lane 3). When an Akt
immunoprecipitate was analyzed, the p54 JNK isoform was
found to be coimmunoprecipitated with Akt, but the p46 iso-
form was not detected (Fig. 4A, lanes 1 and 2). The association
between Akt and JNK was independent of CSF-1 treatment of
the cells.
Immune kinase assays were performed with both anti-Akt
and anti-JNK antibodies for immunoprecipitation (Fig. 4B).
This analysis demonstrated that the Akt immunoprecipitate
contained c-jun N-terminal kinase activity and that this activity
was inhibited three- to fourfold by treatment of cells with 100
mM LY294002 (Fig. 4B, top left panel). The JNK immunopre-
cipitate had histone H2B kinase activity that was inhibited
2.5-fold by LY294002 treatment, indicating that Akt could be
coprecipitated with JNK (Fig. 4B, right middle panel). In ad-
dition, the JNK immunoprecipitate contained ets-2 kinase ac-
tivity that was inhibited twofold by LY294002 treatment. These
results implied that the p54 isoform of JNK is an ets-2 kinase
found in a complex with Akt in macrophages.
Extracts prepared from wild-type macrophages were exam-
ined in order to establish if Akt and p54 JNK were in a com-
plex in normal as well as me-v cells (Fig. 4C). The analysis
FIG. 3. An Akt immunoprecipitate catalyzes phosphorylation of ets-2 at po-
sition threonine 72, and LY294002 inhibits ets-2 phosphorylation in me-v mac-
rophages. (A) Akt immune kinase assays performed with RAW264 cells using
histone H2B, ets-2 T72, and ets-2 A72 as substrates (panels as indicated). Akt
was isolated from 107 cells grown in normal medium (lane 1), treated for 5 min
with 300 mM pervanadate (pervan) (lane 2), or treated for 5 min with both 300
mM pervanadate and 50 or 100 mM PI 3-kinase inhibitor LY294002 (LY) (lanes
3 and 4, respectively). The sample in lane 5 is a control in which Akt antibody was
not included. The bottom panel is a Western blot performed with the Akt
antibody to demonstrate that Akt was present in all samples. (B) Akt immune
kinase assays performed on 107 wild-type (lanes 1 to 4) or me-v primary macro-
phages (lanes 5 to 8) with histone H2B or ets-2 substrates (as labeled). Cells were
grown without CSF-1 for 24 h and then stimulated with 50 ng of CSF-1 per ml
for the times indicated. LY294002 (100 mM) was included 30 min prior to
addition of CSF-1 (lanes 4 and 8). The bottom panel is a Western blot of the
immunoprecipitated material probed with anti-Akt antibody. (C) The average of
four independent Akt immune kinase assays performed on wild-type (WT [open
bars]) or me-v (shaded bars) macrophages with the ets-2 substrate (including the
experiment shown in 3B). The results are presented relative to wild-type samples
grown in the absence of CSF-1. The error bars indicate the standard deviation.
(D) Western analysis of wild-type (lanes 1 and 2) or me-v (lanes 3 and 4)
macrophages by using the anti-ets-2 pT72-specific antibody (top panel). Cells
were grown in the presence of 50 ng of CSF-1 per ml and treated with 100 mM
LY294002 for 16 h (lanes 1 and 4). The blot shown was reprobed with an anti-Erk
antibody as a sample loading control (bottom panel).
VOL. 20, 2000 REGULATION OF ets-2 BY Akt 8029
revealed that Akt and p54 JNK were in a complex in a CSF-
1-independent fashion (Fig. 4C, top panel, lane 1 versus lanes
2 and 3). Immune kinase assays of the Akt immunoprecipitate
indicated that JNK activity, measured with c-jun substrate, was
rapidly activated three- to fourfold within 5 min of CSF-1
stimulation of cells (Fig. 4C, lanes 2). The Akt-associated JNK
activity returned to basal levels within 30 min (Fig. 4C, middle
panel, lanes 3). The activation of JNK in the Akt immunopre-
cipitate in wild-type cells paralleled histone H2B kinase activity
(Fig. 3B, lanes 1 to 3, and bottom panel, 4C, lanes 1 to 3), as
well as ets-2 kinase activity (Fig. 3B, lanes 1 to 3).
CSF-1-independent survival of me-v cells depends on PI
3-kinase signaling. The well-established role of the PI 3-ki-
nase/Akt pathways in preventing cell apoptosis (12, 13, 27)
suggested that me-v macrophages might be resistant to cell
death induced by withdrawal of exogenous CSF-1 when com-
pared to normal cells. To test this prediction, the survival of
me-v macrophages in response to CSF-1 withdrawal was stud-
ied (Fig. 5A). Following 72 h of CSF-1 withdrawal, less than
10% of wild-type BMMs survived, while 70 to 80% of me-v
cells were viable (Fig. 5A). The results shown were obtained
with the nuclear morphology assay to determine the extent of
cell apoptosis and were independently confirmed by using the
sub-G0 flow cytometry and cell viability assays (see Materials
and Methods; data not shown).
To assess whether me-v macrophage survival depended on
PI 3-kinase signaling, cells were treated with the drug
LY294002, and cell apoptosis was determined (Fig. 5B). These
experiments demonstrated that cell apoptosis was triggered in
both wild-type and me-v cells grown in the presence of CSF-1
following 24 h of LY294002 treatment, with approximately 18
and 25% of macrophages, respectively, found to undergo ap-
optosis, compared to less than 2% of cells that were not treated
with the drug (Fig. 5B). The effect of LY294002 on me-v and
wild-type macrophages grown in the absence of CSF-1 was
even more dramatic, with 64 and 40% of cells apoptotic after
24 h, respectively, in contrast to cells not treated with the PI
3-kinase inhibitor (Fig. 5B). The results shown were obtained
by using the flow cytometry sub-G0 assay and were indepen-
dently confirmed by using nuclear morphology as an index for
apoptosis (data not shown). The results suggested that both
wild-type and me-v cells were dependent on PI 3-kinase sig-
naling to maintain cell survival.
The expression and activation of the CSF-1 receptor, c-fms,
were studied in me-v cells grown in the absence of CSF-1 (Fig.
5C). The experiment indicated that c-fms was expressed; how-
ever, tyrosine-phosphorylated c-fms was not detected in cells
following 8 to 72 h of growth in the absence of CSF-1 (Fig. 5C,
lanes 2 to 5, 7, and 8). Readdition of CSF-1 to cells grown in
the absence of CSF-1 for 24 h resulted in detection of phos-
phorylated tyrosine residues within 10 min (Fig. 5C, lane 6).
The Bcl-x gene is a target of Akt and ets-2 signaling. How
might the phosphorylation of ets-2 by the PI 3-kinase/Akt
pathway contribute to the survival of me-v cells? One hypoth-
esis is that PI 3-kinase/Akt pathway-dependent phosphoryla-
tion of ets-2 leads to activation of genes that prevent apoptosis
in me-v macrophages. The Bcl-x gene was selected as a poten-
tial target gene for Akt and ets-2 action in me-v cells, because
this antiapoptotic gene was reported to be an ets-2 target in the
macrophage cell line BAC-1.2F5 (38). Northern analysis of
RNA isolated from me-v macrophages revealed that Bcl-x
RNA was expressed independently of exogenous CSF-1 (Fig.
6A, lanes 3 to 6), unlike wild-type cells, in which Bcl-x expres-
sion was dependent on CSF-1 (Fig. 6A, lanes 1 and 2).
To examine whether the Bcl-x gene was directly regulated by
ets-2 and Akt, a mouse Bcl-x proximal promoter reporter was
studied in transient cotransfection experiments with the com-
bination of a dominant-active form of Akt and ets-2 (Fig. 6B).
The Bcl-x sequences studied comprised the region located
approximately 600 bp upstream of the transcription start site
fused to a firefly luciferase reporter gene (pGLK2-0.6R) (19).
A myristylated, membrane-targeted form of Akt was used for
the analysis (5). This constitutively active form of Akt was able
to activate the Bcl-x reporter around 3-fold (Fig. 6B), while
ets-2 alone stimulated the Bcl-x reporter 15-fold in this set of
experiments. The combination of membrane-targeted Akt and
ets-2 was able to superactivate the Bcl-x reporter, with an
average induction of 97-fold observed (Fig. 6B [ets2-T72 pan-
el]). An ets-2 protein with the phosphoacceptor site at threo-
nine 72 mutated to alanine 72 was not able to superactivate the
Bcl-x reporter in combination with myristylated Akt in the
transient assay (Fig. 6B [ets2-A72 panel]).
The effect of LY294002 treatment on Ets-2 target gene ex-
pression was analyzed in me-v macrophages by Northern anal-
ysis (Fig. 6C). The experiments demonstrated that 16 h after
LY294002 treatment, the levels of expression of uPA and Bcl-x
mRNA were decreased approximately eightfold in me-v mac-
rophages (Fig. 6C). Thus, ets-2 phosphorylation and target
gene expression correlated with PI 3-kinase-dependent cell
survival in me-v cells.
DISCUSSION
The finding that MEK-1 and Erks were not activated by
CSF-1 in me-v BMMs (31) suggested that the me-v model
FIG. 4. p54 JNK coimmunoprecipitates with Akt and is an ets-2 kinase in
me-v macrophages. (A) Akt immunoprecipitates (lanes 1 and 2) were analyzed
by Western blotting with the anti-JNK antibody. Cells were grown in the absence
of CSF-1 for 24 h (lanes 1) or continuously in the presence of 50 ng of CSF-1 per
ml (lanes 2). Whole-cell extracts were also prepared and analyzed on a lane on
the same gel (lane 3). The positions of the p54 and p46 JNK isoforms are
indicated. (B) Akt (left panels) or JNK (right panels) immune kinase assays
performed on me-v macrophages using N-terminal c-jun, ets-2 “pointed,” and
histone H2B substrates, as indicated. Cells were grown continually in the pres-
ence of 50 ng of CSF-1 per ml and treated with 100 mM LY294002 (LY) for 16 h
as indicated. The bottom panel is a Western blot with an anti-JNK antibody to
demonstrate that equivalent amounts of JNK were present in untreated and
LY294002-treated samples. IP, immunoprecipitate. (C) Wild-type BMMs were
deprived of CSF-1 for 24 h (lane 1) and then restimulated with CSF-1 for 5 or 30
min (lanes 2 and 3, respectively). Cell extracts were prepared and incubated with
anti-Akt antibody. Half of the Akt immunoprecipitate was analyzed by Western
blotting with a JNK antibody (top panel, p54). The other half was assayed for
kinase activity by using both the c-jun (middle panel) and histone H2B substrates
(lower panel).
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system might provide a unique genetic background that would
facilitate identification of Erk-independent signaling pathways
that activate ets-2 in response to CSF-1. Analysis of macro-
phages derived from me-v mice unexpectedly demonstrated
that phosphorylation of ets-2 was constitutive and independent
of CSF-1 in these cells. In addition, the well-characterized ets-2
target genes coding for uPA, SR, and Bcl-x were constitutively
expressed.
Erk-independent phosphorylation of ets-2 and activation of
target genes in me-v macrophages were linked to the constitu-
tive activation of the PI 3-kinase/Akt pathway and of an Akt-
associated ets-2 (threonine 72) kinase activity. Furthermore,
the p54 JNK isoform coimmunoprecipitated with Akt in mac-
rophages and immune kinase assays demonstrated that JNK
could catalyze phosphorylation of an ets-2 substrate dependent
on PI 3-kinase signaling. Thus, in addition to being a substrate
for the Raf/Erk pathway (16), ets-2 is a substrate for a novel PI
3-kinase/Akt/p54 JNK signaling pathway. The PI 3-kinase
pathway is transiently activated by CSF-1 in wild-type cells, but
is constitutively active in me-v macrophages. These results also
highlight a difference between JNK p46 and p54 isoforms and
suggest that the extended C-terminal domain of the p54 iso-
form may be involved in the association between Akt and JNK.
We have previously demonstrated that an epitope-tagged
version of p54 JNK2 expressed in fibroblasts was incapable of
catalyzing the phosphorylation of ets-2 substrate under condi-
tions in which the PI 3-kinase pathway was not activated (16).
JNK2 is reported to bind to the N-terminal portion of c-jun 25
times more efficiently than JNK1, and this direct interaction
increases phosphorylation of c-jun by JNK2 relative to JNK1
(25). ets-2 was likely a poor substrate for JNK2 in the previ-
ously reported experiments, because it does not directly form a
complex with JNK2. Taken with the results presented here,
these data suggest the hypothesis that JNK substrate specificity
is altered by association with the Akt complex. An adapter
protein present in the Akt-JNK complex may recruit ets-2 and
allow direct phosphorylation by p54 JNK even in the absence
of a high-affinity interaction between ets-2 and JNK. Thus, the
FIG. 5. Increased survival of me-v macrophages after CSF-1 withdrawal dependent on the PI 3-kinase pathway. (A) BMMs derived from normal and me-v mice were
cultured in media lacking CSF-1 for the indicated times (2 3 106 cells plated per time point), fixed, and stained with 10 mM bis-benzimide. Fluorescent microscopy
was used to distinguish the nuclear morphology of viable cells and apoptotic cells (see Materials and Methods). Results of the average of three experiments are shown,
presented as the percentage of cells surviving. Error bars indicate the standard deviation. WT, wild type. (B) Fraction of apoptotic cells (2 3 106 cells plated) following
treatment with 100 mM LY294002 for 24 h (hatched bars) in the presence or absence of 50 ng of CSF-1 per ml as indicated. Apoptosis was quantified by using the flow
cytometry sub-G0 assay (see Materials and Methods). The average result of three experiments is represented. Error bars indicate the standard deviation of
measurements. (C) me-v macrophages were grown continuously in the presence of CSF-1 (lane 1) or in media lacking CSF-1 for 8, 12, 16, 24 (lanes 2 to 5), 48, or 72 h
(lanes 7 and 8). Cells starved of CSF-1 for 24 h had CSF-1 added to the medium for 10 min before harvest (lane 6). c-fms was immunoprecipitated with a specific
antibody. The immunoprecipitate was divided in half and analyzed by Western blotting with either the c-fms (fms) antibody (top panel) or antiphosphotyrosine (pTY)
antibody (bottom panel).
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in vivo substrate range for the 10 characterized JNK isoforms
may be dictated by the signaling complex with which they
associate, in addition to high-affinity physical interactions with
substrates (20). Further characterization of the Akt-JNK com-
plex in macrophages will determine if this model is valid.
Our results imply that SHP-1 is a negative regulator of the PI
3-kinase/Akt/JNK pathway in macrophages. However, the
question of what is the actual substrate for SHP-1 that lies
upstream of the PI 3-kinase pathway remains open. The alter-
ations in signaling in cells deficient in SHP-1 function are likely
pleiotropic, reflecting that SHP-1 regulates multiple signaling
pathways. In addition to c-fms (10), the GM-CSF receptor
(23), JAK-2 (22), and negative-signaling receptors p91/PIR-B
and SHPS-12 (6, 42, 46) have all been reported as substrates
for SHP-1 and all can potentially activate the PI 3-kinase/Akt
pathway. The outcome of effects on multiple ligand-receptor
FIG. 6. The mouse Bcl-x gene is a target of Akt–ets-2 action. (A) Total RNA was isolated from wild-type or me-v BMMs (two independent RNA samples each
prepared from cells pooled from two mice). Cells were cultured in medium lacking CSF-1 for 24 h (lanes 1, 3, and 5) or restimulated with CSF-1 for 16 h (lanes 2, 4,
and 6). RNA was analyzed by Northern blotting with a probe specific for mouse Bcl-x cDNA. A major 2.6-kb Bcl-x mRNA species was detected. Blots were reprobed
with a mouse g-actin probe as a sample loading control (bottom panel). (B) Transient transfections were performed in RAW264 cells. In each experiment, 4 mg of the
Bcl-x reporter pGL2-0.6R was transfected in the presence or absence of 1 mg of the ets-2 expression vector pGCN-ets-2 (either wild-type T72 or mutated A72 forms,
as indicated), 0.2 mg of a cytomegalovirus expression vector for the myristylated form of Akt (myr-Akt), or the combination of both ets-2 and myr-Akt as indicated.
The average result of four experiments is shown. Error bars indicate the standard deviation of the measurements. (C) RNA was prepared from me-v BMMs that were
untreated (lane 1) or treated with 100 mM LY294002 for 16 h (lane 2) and analyzed by Northern blotting. Blots were hybridized with probes specific for uPA or Bcl-x,
as indicated and then reprobed with g-actin (a loading control).
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pairs is likely aberrant signaling, leading not only to PI 3-ki-
nase–Akt activation, but also to abrogation of MEK-1–Erk
signaling.
Recent work has revealed that, in some cell types, the PI
3-kinase/Akt pathway can negatively regulate the raf/MEK-1/
Erk pathway via phosphorylation of regulatory sites within
c-raf (36, 51). Our finding that the PI 3-kinase pathway is
constitutively upregulated in me-v macrophages provides a mo-
lecular explanation for the lack of CSF-1-dependent MEK-1
and Erk activity in me-v macrophages. More interestingly,
these results demonstrate an additional level of cross talk be-
tween these two pathways, the phosphorylation and activation
of ets-2. At least one nuclear target of raf-Erk signaling re-
mains phosphorylated and active in spite of the potential neg-
ative cross talk with the PI 3-kinase/Akt pathway in me-v mac-
rophages.
Why is ets-2 a target for both raf and Akt signaling path-
ways? The data presented here indicate a link between the PI
3-kinase and Akt signaling pathways that promote me-v mac-
rophage survival and ets-2 activation of antiapoptotic targets
like Bcl-x. Perhaps the raf/MEK/Erk and PI 3-kinase/Akt path-
ways share some common targets to ensure that, under the
physiological conditions that dictate negative interactions be-
tween the two pathways, programmed cell death is not trig-
gered inappropriately. Work demonstrating that the proapop-
totic factor BAD may be a target for both of these signaling
pathways supports this idea (15, 37).
ets-2 is one of several transcription factors that have recently
been identified as targets of Akt action in mammalian cells,
including forkhead transcription factors, the cyclic AMP-re-
sponsive factor CREB, and NF-kB (9, 14, 26, 29, 40). Our
results indicate that increased cell survival contingent on Akt-
JNK activation of ets-2 may in part account for the massive
overaccumulation of macrophages and subsequent pathology
observed in me-v mice and therefore may have implications for
understanding the molecular basis of macrophage-mediated
damage in human inflammatory diseases such as rheumatoid
arthritis (45).
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